Seven Innovative Biopharma Companies Secure Funding, Led by Seismic Therapeutics' $121M Series B

Dec 11, 2023 17:04 CST Updated 17:04

Seismic Therapeutic

Immunotherapy Developer

Odyssey Therapeutics

Developer of Immunomodulators and Oncology Drugs

▎Edited by the WuXi AppTec content team

According to incomplete statistics from Innovation Radar, last week (December 4 to December 10), there were 16 disclosed financing events in the global healthcare sector, with a total amount exceeding 3.3 billion yuan. In terms of amount, there were 7 financings of 100 million yuan or more, with the highest potential financing amount coming from Seismic Therapeutic's $121 million Series B financing. According to the disclosed financing rounds, there were 10 early-stage financings (before Series B) and 4 mid-to-late stage financings (Series B and later). A total of 7 companies in the biopharmaceutical field received financing, involving drug types including immunotherapy, radionuclide therapy, microbiome gene therapy, etc.

#01

Seismic Therapeutic Completes $121 Million Series B Financing

Keywords: Immunotherapy

Latest Financing: $121 Million Series B

This round of investment institutions: Alexandria Venture Investments, Amgen Ventures, Bessemer Venture Partners, Boxer Capital, Polaris Partners, etc.

On December 4, Seismic Therapeutic announced the completion of a $121 million Series B financing. Seismic Therapeutic is an immunotherapy research and development company dedicated to...Integration of Machine Learning into Drug Development for Immuno-Biologics。In 2023, the company was successively selected by BioSpace, a well-known media in the biopharmaceutical industry.2023 New Generation of Biotech Rising StarsAs selected by Endpoints2023 "Most Promising Newcomer in Biopharmaceuticals"List.Currently, the company has independently built the IMPACT platform with machine learning capabilities to meet the research and development needs of immunotherapy drugs. In addition, the company has developed a new generation of protease treatment methods based on its IgSc enzyme program-created novel pan-IgG proteases for treating acute and chronic autoantibody-mediated diseases. It is reported that this round of financing will help build the company’s machine learning platform and advance the clinical trials of its protease lead projects.

#02

Odyssey Therapeutics Completes $101 Million Series C Financing

Keywords: New drugs for cancer and immune diseases

Latest Financing: $101 Million Series C Financing

This round of investment institutions: Alexandria Venture Investments, Ascenta Capital, OrbiMed, BlackMars Capital, Catalio Capital Management, Colt Ventures, Foresite Capital, etc.

On December 5, Odyssey Therapeutics announced the completion of a $101 million Series C financing. Odyssey Therapeutics focuses on developing a new generation of immune modulators and oncology drugs. By targeting and controlling the effective signaling nodes that drive diseases, the company is committed to transforming existing treatment paradigms and bringing new therapies to patients with very limited treatment options.Combining Artificial Intelligence (AI) Technology with Machine LearningThe company is building a drug discovery engine for molecular design, a functional genomics platform for discovering new targets, and a proprietary covalent library containing natural products targeting various amino acids and molecular glues. It is reported that the proceeds from this round of financing will be used to advance the research and development of its precision immune modulators and oncology drugs.

#03

ARTBIO Completes $90 Million Series A Financing

Keywords: Radionuclide Therapy

Latest Financing: $90 Million Series A Round

This round of investment institutions: F-Prime Capital, Omega Funds, Third Rock Ventures

On December 7, ARTBIO announced the completion of a $90 million Series A financing round.ARTBIO is a radiopharmaceuticals R&D company,Dedicated to the Development of Alpha Radioactive Ligand Therapies (ARTs) to Improve Cancer Patient Outcomes。The company selects α-radioisotope (Pb212) and tumor-specific targets to develop highly targeted therapeutic drugs.Pb212 is an ideal isotope with a short lifespan, which fits itsThe characteristics of small-molecule carriers allow for rapid delivery of radiation to tumors most likely to respond, while maintaining high stability within their carrier molecules, which can have a potentially positive impact on safety and efficacy.ARTBIO is advancing three pipeline projects, with the lead project AB001 currently entering the human trial phase.It is reported that the funds from this round of financing will be used for the continuous development of the company's products.

#04

Eligo Bioscience Completes $30 Million Series B Financing

Keywords: Microbiome Gene Therapy

Latest Financing: $30 Million Series B

This round of investment institutions: Bpifrance, Khosla Ventures, Sanofi Ventures, Seventure Partners

On December 5, Eligo Bioscience announced the completion of a $30 million Series B financing round. Eligo Bioscience is committed toDevelopment of In Vivo Gene Editing Therapies for the Microbiome and Antibiotics, aimed at treating bacterial-related diseases. The company's self-developed technology platform enables the delivery and expression of therapeutic DNA in target bacterial populations within the microbiome, modulating the composition and function of the microbiome in situ to address human diseases with higher precision. It is reported that this round of financing will be used to accelerate the development of projects targeting inflammatory diseases, promote the acquisition of early human data in clinical trials, and expand the company’s drug pipeline in chronic diseases and oncology.

#05

Rongcan Bio Completes Over 100 Million Yuan in Series A Financing

Keywords: Nucleic Acid and Gene Medicines

Latest Financing: Over 100 Million Yuan in Series A Financing

This round of investment institutions: Huafang Capital, Shanxi Growth Fund, Yuexiu Industrial Fund, Zhangjiagang Jintai Jinhong Fund

On December 6, R-Cure Biotech announced the completion of an A-round financing of over 100 million yuan. R-Cure Biotech is committed to the development and industrialization of gene (nucleic acid) drugs, with technical expertise covering nucleic acid sequence design and optimization, large-scale synthesis of mRNA solutions, design and preparation of delivery carriers, as well as the design and research of nucleic acid drugs. Currently, the company...Built a Ribonucleic Acid Treatment Technology Platform (RTP) and has developed multiple innovative drug pipelines based on messenger nucleic acid (mRNA).; Meanwhile, R-Cure Biotech also owns a nucleic acid delivery technology platform and has independent intellectual property rights in nucleic acid delivery. R-Cure Biotech has made progress in the fields of cationic lipid structure, formulation component ratio, indication applications, and RNA sequences, obtaining multiple patent grants and PCT patent acceptances. It is reported that the funds from this round of financing will be used to accelerate product development and team building for R-Cure Biotech, as well as to advance the leading pipeline into clinical research.

Readers, please star ⭐Chuangjianhui to receive updates第一时间收到推送.

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress of global biopharmaceuticals and health. This article is for the purpose of information exchange only, and the views in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article. This article is not a recommendation for treatment plans. If you need guidance on treatment options, please visit a regular hospital.

Copyright Statement: This article was compiled and edited by the WuXi AppTec content team based on publicly available information. Individuals are welcome to share it on their social media feeds, but unauthorized reprints or reproductions by media or institutions in any form to other platforms are strictly prohibited. For reprint authorization, please contact"Chuangjian Hui"Contact us through the WeChat Official Account comments.

More Data Content Recommendations

Click "InSee", Sharing New Health Trends from Insight Innovation"